Results 211 to 220 of about 24,933,173 (248)

Multilingual Digital Search Behavior Reveals Cultural Disparities in Vitiligo Information Needs in Germany

International Journal of Dermatology, EarlyView.
Multilingual vitiligo‐related Google search queries in Germany (October 2019–May 2023) were extracted and thematically coded across German, English, Turkish, Arabic, Russian, and Polish. Relative patterns highlighted language‐specific emphases in treatment information, camouflage, depigmentation, psychosocial burden, and faith/home‐remedy terms ...
Lilian Rauch, Christine Gasteiger, Markus Böhm, Georg Pliszewski, Tilo Biedermann, Alexander Zink   +5 more
wiley   +1 more source

Impact of Dupilumab and Upadacitinib Treatment on Epigenetic and Transcriptomic Alterations in Skin‐Homing T Cells of Atopic Dermatitis Patients

Clinical &Experimental Allergy, EarlyView.
Ahmed M. I. Elfiky, Hidde M. Smits, Marlot van der Wal, Coco Dekkers, Celeste M. Boesjes, Julia Drylewicz, Marjolein de Bruin‐Weller, Femke van Wijk   +7 more
wiley   +1 more source

Early On‐Treatment Change in SALT as a Pragmatic Predictor of Ritlecitinib Response in Moderate‐To‐Severe Alopecia Areata: A Real‐World Cohort Study

International Journal of Dermatology, EarlyView.
Ritlecitinib induced rapid clinical improvement in moderate‐to‐severe alopecia areata in real‐world practice. Early change in SALT at Week 12 strongly discriminated Week‐24 responders, supporting a pragmatic treat‐to‐target checkpoint, alongside improvements in clinician‐reported and patient‐reported outcomes and a favorable safety profile.
Giuseppe Gallo, Isotta Giunipero di Corteranzo, Pietro Quaglino, Simone Ribero, Francois Rosset   +4 more
wiley   +1 more source

The Psoriasis–Eczema Interface: Clinical Classification and Therapeutic Implications From a Bicentric Experience

International Journal of Dermatology, EarlyView.
The psoriasis–atopic dermatitis interface: four clinical phenotypes (coexisting, overlapping, biologic‐induced eczema, dupilumab‐induced psoriasis) across 105 patients from two Italian tertiary centers. JAK inhibitors achieved the highest response rates across all phenotypes, reflecting their mechanistic rationale targeting shared JAK‐STAT downstream ...
Michela D'Agostino, Gennaro Marco Falco, Eleonora De Luca, Clara De Simone, Alessandro Di Stefani, Maddalena Napolitano, Ketty Peris, Matteo Megna, Giacomo Caldarola   +8 more
wiley   +1 more source

Successful Management of Persistent DRESS with Tofacitinib: Two Case Reports

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Marc Hernández‐Santacana, Ignasi Martí‐Martí, Victoria Amat‐Samaranch, Irene Fuertes de Vega, Priscila Giavedoni, José M. Mascaró Jr   +5 more
wiley   +1 more source

Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]

Postgraduate Medicine, 2013
Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovsek
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis

Cochrane Database of Systematic Reviews, 2015
Myelofibrosis is a bone marrow disorder characterized by excessive production of reticulin and collagen fiber deposition caused by hematological and non-hematological disorders. The prognosis of myelofibrosis is poor and treatment is mainly palliative.
Arturo J, Martí-Carvajal, Vidhu, Anand, Ivan, Solà   +2 more
openaire   +4 more sources

Covalent Modification of the JH2 Domain of Janus Kinase 2

ACS Medicinal Chemistry Letters, 2022
Probe molecules that covalently modify the JAK2 pseudokinase domain (JH2) are reported. Selective targeting of JH2 domains over the kinase (JH1) domains is a necessary feature for ligands intended to evaluate JH2 domains as therapeutic targets. The JH2 domains of three Janus kinases (JAK1, JAK2, and TYK2) possess a cysteine residue in the catalytic ...
Sean P. Henry, Maria-Elena Liosi, Joseph A. Ippolito, Fabian Menges, Ana S. Newton, Joseph Schlessinger, William L. Jorgensen   +6 more
openaire   +2 more sources

Downregulation of KCNQ4 by Janus Kinase 2

The Journal of Membrane Biology, 2013
Janus kinase-2 (JAK2) participates in the signaling of several hormones, growth factors and cytokines. Further stimulators of JAK2 include osmotic cell shrinkage, and the kinase activates the cell volume regulatory Na(+)/H(+) exchanger. The kinase may thus participate in cell volume regulation. Cell shrinkage is known to inhibit K(+) channels.
Hosseinzadeh, Zohreh, Sopjani, Mentor, Pakladok, Tatsiana, Bhavsar, Shefalee K., Lang, Florian   +4 more
openaire   +3 more sources

Janus kinase 2 inhibitors in myeloproliferative disorders

Expert Opinion on Investigational Drugs, 2010
JAK2 is an obligatory kinase for the proliferation and differentiation of erythroid cells and megakaryocytes thus representing a relevant therapeutic target for agents that specifically inhibit its activity particularly in myeloproliferative disorders (MPD) harboring JAK2(V617F) mutations.We discuss the physiopathology of the JAK2 signaling pathway and
Lucia E, Recchia AG, Gentile M, Bossio S, Vigna E, Mazzone C, Madeo A, Morabito L, Gigliotti V, De Stefano L, Caruso N, Servillo P, Franzese S, Bisconte MG, Gentile C, Morabito F.   +15 more
openaire   +3 more sources